HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
出版年份 2023 全文链接
标题
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
作者
关键词
-
出版物
ANTIVIRAL THERAPY
Volume 28, Issue 5, Pages -
出版商
SAGE Publications
发表日期
2023-09-26
DOI
10.1177/13596535231201162
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study
- (2023) Edgar T Overton et al. CLINICAL INFECTIOUS DISEASES
- Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study
- (2023) Hortensia Álvarez et al. CLINICAL INFECTIOUS DISEASES
- High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I
- (2022) Paul E. Sax et al. AIDS
- Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance
- (2022) Ming-Tain Lai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV
- (2022) Chloe Orkin et al. HIV MEDICINE
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
- (2022) Sorana Segal-Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance
- (2022) Anna Maria Geretti et al. Infectious Diseases and Therapy
- Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
- (2022) Nicolas A Margot et al. JOURNAL OF INFECTIOUS DISEASES
- Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir
- (2022) Stephanie M. Bester et al. mBio
- Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
- (2022) Urvi M. Parikh et al. Current HIV/AIDS Reports
- BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022
- (2022) Laura Waters et al. HIV MEDICINE
- Late diagnosis of HIV in 2022: Why so little change?
- (2022) Simon Collins et al. HIV MEDICINE
- HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)
- (2021) Natalie N. Kinloch et al. Nature Communications
- Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
- (2021) Kirsten L. White et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Avoiding Drug Resistance in HIV Reverse Transcriptase
- (2021) Maria E. Cilento et al. CHEMICAL REVIEWS
- Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with Human Immunodeficiency Virus in a European Cohort
- (2021) Annegret Pelchen-Matthews et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
- (2021) Franco Maggiolo et al. Infectious Diseases and Therapy
- Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection
- (2021) Pedro Cahn et al. AIDS
- Transmitted Drug Resistance Among HIV-1 Diagnoses in the United States, 2014–2018
- (2021) R Paul McClung et al. CLINICAL INFECTIOUS DISEASES
- Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
- (2021) Ronald Rose et al. AIDS
- Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
- (2021) Juan Ambrosioni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
- (2021) Anastasia Selyutina et al. iScience
- Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
- (2020) Globahan Ajibola et al. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE
- Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir
- (2020) Yagai Bouba et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug Resistance
- (2020) Joshua Yi Yeo et al. Viruses-Basel
- Effect of mobile text messages on antiretroviral medication adherence and patient retention in early HIV care: an open-label, randomized, single center study in south Florida
- (2020) Elizabeth M. Sherman et al. AIDS Research and Therapy
- Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases
- (2020) Muge Cevik et al. Open Forum Infectious Diseases
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries
- (2020) Chinyere Okoli et al. SEXUALLY TRANSMITTED INFECTIONS
- Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations
- (2020) Santiago Ávila-Ríos et al. Viruses-Basel
- Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping
- (2020) Neil T. Parkin et al. Viruses-Basel
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
- (2020) Chloe Orkin et al. Lancet HIV
- Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment
- (2020) Ashima Pyngottu et al. CLINICAL INFECTIOUS DISEASES
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
- (2020) Elizabeth Anne Martin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Impact of HIV-1 Drug Escape on the Global Treatment Landscape
- (2019) D.A. Collier et al. Cell Host & Microbe
- A systematic review of the genetic mechanisms of dolutegravir resistance
- (2019) Soo-Yon Rhee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen (STR) Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
- (2019) Erkki Lathouwers et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Management of Virologic Failure and HIV Drug Resistance
- (2019) Suzanne M. McCluskey et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
- (2019) Kristen Andreatta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel
- (2018) Huldrych F Günthard et al. CLINICAL INFECTIOUS DISEASES
- HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy
- (2018) Philip J. Palumbo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
- (2018) Max Lataillade et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
- (2018) Manabu Aoki et al. mBio
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
- (2018) Brinda Emu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
- (2018) Maureen Oliveira et al. Retrovirology
- An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs
- (2017) Erasmus Smit et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Global HIV Antiretroviral Drug Resistance
- (2017) Catherine Godfrey et al. JOURNAL OF INFECTIOUS DISEASES
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
- (2017) Isabelle Malet et al. mBio
- Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis
- (2016) Alexandra U. Scherrer et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 drug resistance and resistance testing
- (2016) Dana S. Clutter et al. INFECTION GENETICS AND EVOLUTION
- Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
- (2016) John Gregson et al. LANCET INFECTIOUS DISEASES
- Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket
- (2015) Yang Su et al. JOURNAL OF VIROLOGY
- Extremely High Mutation Rate of HIV-1 In Vivo
- (2015) José M. Cuevas et al. PLOS BIOLOGY
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Current Perspectives on HIV-1 Antiretroviral Drug Resistance
- (2014) Pinar Iyidogan et al. Viruses-Basel
- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- HIV-1 reverse transcriptase and antiviral drug resistance. Part 2
- (2013) Kalyan Das et al. Current Opinion in Virology
- E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
- (2012) Slim Fourati et al. AIDS
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Spillover adherence effects of fixed-dose combination HIV therapy
- (2012) Teresa Kauf et al. Patient Preference and Adherence
- Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 Protease
- (2011) Max W. Chang et al. JOURNAL OF MOLECULAR BIOLOGY
- Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab
- (2011) J. Toma et al. JOURNAL OF VIROLOGY
- Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity
- (2011) Agnes C. Paquet et al. PLoS One
- Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
- (2010) Ana Canestri et al. CLINICAL INFECTIOUS DISEASES
- Accurately Measuring Recombination between Closely Related HIV-1 Genomes
- (2010) Timothy E. Schlub et al. PLoS Computational Biology
- Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
- (2009) Edward M Gardner et al. AIDS
- Understanding transmitted HIV resistance through the experience in the USA
- (2009) Babafemi Taiwo INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials
- (2008) Sandra de Meyer et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now